ДИАБЕТИЧЕСКАЯ ПОЛИНЕЙРОПАТИЯ: ПАТОГЕНЕЗ, КЛИНИКА, ПОДХОДЫ К ПЕРСОНИФИЦИРОВАННОЙ КОРРЕКЦИИ
https://doi.org/10.21518/2079-701X-2017-17-72-80
Аннотация
В статье дается обзор наиболее современных представлений о патогенезе, клинической картине и терапии диабетических полинейропатий. Приводятся данные об эпидемиологии состояния, классификация диабетических полинейропатий; рассматриваются вопросы симптоматологии, морфологических изменений при данной патологии. Обсуждаются проблемы этиопатогенетической и симптоматической терапии полинейропатий, основанные на результатах многоцентровых клинических исследований.
Об авторах
М. М. Танашян
Научный центр неврологии
Россия
Россия
Доктор медицинских наук, профессор.
Москва
К. В. Антонова
Научный центр неврологии
Россия
Россия
Кандидат медицинских наук.
Москва
А. А. Раскуражев
Научный центр неврологии
Россия
Россия
Кандидат медицинских наук.
Москва
Список литературы
1. Global report on diabetes. World Health Organization, Geneva, 2016. Available from: http://www.who.int/mediacentre/factsheets/fs312/en/Accessed January 3, 2017.
2. Результаты реализации подпрограммы «Сахарный диабет» Федеральной целевой программы «Предупреждение и борьба с социально значимыми заболеваниями 2007–2012 гг.» Под ред. И.И. Дедова, М.В. Шестаковой. Сахарный диабет, 2013, спецвыпуск 2.
3. Дедов И.И., Шестакова М.В., Галстян Г.Р. Распространенность сахарного диабета 2 типа у взрослого населения России (исследование NATION). Сахарный диабет, 2016, 19(2): 104-112.
4. Béjot Y, Giroud M. Stroke in diabetic patients. Diabetes Metab, 2010 Oct, 36(Suppl 3): 84-87. doi: 10.1016/S1262-3636(10)70472-9.
5. Khoury JC et al. Diabetes mellitus: a risk factor for ischemic stroke in a large biracial population. Stroke, 2013 Jun, 44(6): 1500-1504.
6. Phipps MS, Jastreboff AM, Furie K, Kernan WN. The diagnosis and management of cerebrovascular disease in diabetes. Curr Diab Rep, 2012 Jun, 12(3): 314-323.
7. Stino AM, Smith AG. Peripheral neuropathy in prediabetes and the metabolic syndrome. J Diabetes Investig, 2017 Mar 7 [Epub ahead of print]. http: //dx.doi.org/10.1111/jdi.12650, doi: 10.1111/jdi.12650.
8. Román-Pintos LM, Villegas-Rivera G, RodríguezCarrizalez AD, Miranda-Díaz AG, Cardona-Muñoz EG. Diabetic Polyneuropathy in Type 2 Diabetes Mellitus: Inflammation, Oxidative Stress, and Mitochondrial Function. Journal of Diabetes Research, 2016, 2016: 3425617. doi: 10.1155/2016/3425617.
9. Kasznicki J. Advances in the diagnosis and management of diabetic distal symmetric polyneuropathy. Archives of Medical Science : AMS, 2014, 10(2): 345-354.
10. Аметов А.С. Сахарный диабет 2 типа: проблемы и решения. 2-е изд., перераб. и доп. М., 2014. Гл. 22: 597-620.
11. Meyr AJ, Spiess KE. Diabetic Driving StudiesPart 1: Brake Response Time in Diabetic Drivers With Lower Extremity Neuropathy. J Foot Ankle Surg, 2017 May – Jun, 56(3): 568-572. doi: 10.1053/j.jfas.2017.01.042.
12. Spiess KE, Sansosti LE, Meyr AJ. Diabetic Driving Studies-Part 2: A Comparison of Brake Response Time Between Drivers With Diabetes With and Without Lower Extremity Sensorimotor Neuropathy. J Foot Ankle Surg, 2017 May – Jun, 56(3): 573-576. doi: 10.1053/j.jfas.2017.01.043.
13. Sansosti LE, Spiess KE, Meyr AJ. Diabetic Driving Studies-Part 3: A Comparison of Mean Brake Response Time Between Neuropathic Diabetic Drivers With and Without Foot Pathology. J Foot Ankle Surg, 2017 May – Jun, 56(3): 577-580. doi: 10.1053/j.jfas.2017.01.044.
14. Standards of Medical Care in Diabetes, 2015 Edition. Microvascular Complications and Foot Care. Diabetes Care, 2015, 38(Supp. 1): 58-66.
15. Perkins BA, Olaleye D, Bril V. Carpal tunnel syndrome in patients with diabetic polyneuropathy. Diabetes Care, 2002 Mar, 25(3): 565-569.
16. Shaw JE, Zimmet PZ. The epidemiology of diabetic neuropathy. Diabetes Reviews, 1999, 7: 245-252.
17. Dyck PJ, Kratz KM, Karnes JL et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology, 1993, 43: 817-824.
18. Aaberg ML, Burch DM, Hud ZR, Zacharias MP. Gender differences in the onset of diabetic neuropathy. J Diabetes Complications, 2008 Mar-Apr, 22(2): 83-87.
19. Строков И.А., Мельниченко Г.А., Альбекова Ж.С. и др. Распространенность и факторы риска развития диабетической полиневропатии у стационарных больных сахарным диабетом 1-го типа. Нервно-мышечные болезни, 2012, 1: 25-31.
20. Ang L, Jaiswal M, Martin C, Pop-Busui R. Glucose control and diabetic neuropathy: lessons from recent large clinical trials. Curr Diab Rep, 2014, 14: 528.
21. Martin CL, Albers JW, Pop-Busui R, DCCT/EDIC Research Group. Neuropathy and related findings in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study. Diabetes Care, 2014, 37: 31-38.
22. Ismail-Beigi F, Craven T, Banerji MA et al., ACCORD Trial Group. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet, 2010, 376: 419-430.
23. Patel A, MacMahon S, Chalmers J et al. ADVANCE Collaborative Group.Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med, 2008, 358: 2560-2572.
24. Duckworth W, Abraira C, Moritz T et al., VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med, 2009, 360: 129-139.
25. Gaede P, Lund-Andersen H, Parving HH, Peders en O Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med, 2008, 358: 580-591.
26. Rajan RS, de Gray L, George E. Painful diabetic neuropathy. Contin Educ Anaesth Crit Care Pain, 2014, 14(5): 230-235.
27. Smith AG, Russell J, Feldman EL, et al. Lifestyle intervention for pre-diabetic neuropathy. Diabetes Care, 2006, 29: 1294-1299.
28. Singleton JR, Smith AG. Neuropathy associated with prediabetes: what is new in 2007? Curr Diab Rep, 2007, 7: 420-424.
29. Smith AG, Singleton JR. Impaired glucose tolerance and neuropathy. Neurologist, 2008, 14: 23-29.
30. Rajabally YA. Neuropathy and impaired glucose tolerance: an updated review of the evidence. Acta Neurol Scand, 2011, 124: 1-8.
31. Horowitz SH. Recent clinical advances in diabetic polyneuropathy. Curr Opin Anaesthesiol, 2006, 19: 573-578.
32. Pittenger GL, Mehrabyan A, Simmons K et al. Small fiber neuropathy is associated with the metabolic syndrome. Metab Syndr Relat Disord, 2005, 3: 113-121.
33. Kuroda N, Taniguchi H, Baba S, Yamamoto M. The pupillary light reflex in borderline diabetics. J Int Med Res, 1989, 17: 205-211.
34. Ziegler D, Rathmann W, Dickhaus T, Meisinger C, Mielck A, for the KORA Study Group. Prevalence of polyneuropathy in pre-diabetes and diabetes is associated with abdominal obesity and macroangiopathy: the MONICA/ KORA Augsburg Surveys S2 and S3. Diabetes Care, 2008, 31: 464-469.
35. Grundy SM. Pre-diabetes, metabolic syndrome, and cardiovascular risk. J Am Coll Cardiol, 2012, 59(7): 635-643.
36. Bhutani J, Chakinala RC, Bhutani S, Sachdeva S. Endocrine and metabolic disease: Confocal microscopy as a diagnostic aid. Indian J Endocrinol Metab, 2015 Jan-Feb, 19(1): 171-173.
37. Asghar O, Petropoulos IN, Alam U, Jones W, Jeziorska M, Marshall A et al. Corneal confocal microscopy detects neuropathy in subjects with impaired glucose tolerance. Diabetes Care, 2014, 37: 2643-2646.
38. Edwards K, Pritchard N, Dehghani C et al. Corneal confocal microscopy best identifies the development and progression of neuropathy in patients with type 1 diabetes. J Diabetes Complications, 2017 May 5. pii: S1056-8727(16)30705-X. doi: 10.1016/j.jdiacomp.2017.04.025. [Epub ahead of print].
39. Митрофанова И.Н. Особенности развития и течения дистальной полинейропатии у больных сахарным диабетом первого типа. Автореф. дисс. канд. мед. наук. М., 2008.
40. Dyck PJ , Clark VM, Overland CJ et al. Impaired glycemia and diabetic polyneuropathy: The OC IG Survey. Diabetes Care, 2012 Mar, 35: 584.
41. Pourhamidi K, Dahlin LB, Englund E, Rolandsson O.No Difference in Small or Large Nerve Fiber Function Between Individuals With Normal Glucose Tolerance and Impaired Glucose Tolerance. Diabetes Care, 2013 April, 36(4): 962-964.
42. Sun Im, Sung-Rae Kim, Joo Hyun Park et al. Assessment of the Medial Dorsal Cutaneous, Dorsal Sural, and Medial Plantar Nerves in Impaired Glucose Tolerance and Diabetic Patients With Normal Sural and Superficial Peroneal Nerve Responses. Diabetes Care, 2012, 35(4): 834-839.
43. Brownrigg JR, de Lusignan S, McGovern A et al. Peripheral neuropathy and the risk of cardiovascular events in type 2 diabetes mellitus. Heart, 2014 Dec, 100(23): 1837-1843.
44. Cohen JA, Estacio RO, Lundgren RA et al. Diabetic autonomic neuropathy is associated with an increased incidence of strokes. Auton Neurosci, 2003, 108(1-2): 73.
45. Dzau VJ, Antman EM, Black HR, Hayes DL, Manson JE,Plutzky J, Popma JJ, Stevenson W. The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part I: Pathophysiology and clinical trial evidence (risk factor s through stable coronary artery disease). Circulation, 2006 Dec 19, 114(25): 2850-2870.
46. Дедов И.И., Шестакова М.В. Феномен «метаболической памяти» в прогнозировании риска развития сосудистых осложнений при сахарном диабете. Терапевтический архив, 2015, 10: 4-10.
47. Handy DE, Castro R, Loscalzo J. Epigenetic modifications: basic mechanisms and role in cardiovascular disease. Circulation, 2011, 123: 2145-2156.
48. Paneni F, Costantino S, Cosentino F. p66(Shc)induced redox changes drive endothelial insulin resistance. Atherosclerosis, 2014 Oct, 236(2): 426-429. doi: 10.1016/j.atherosclerosis.2014.07.027. Epub 2014 Aug 5.
49. Paneni F, Volpe M, Lüscher TF, Cosentino F. SIRT1, p66Shc, and Set7/9 in Vascular Hyperglycemic Memory: Bringing All the Strands Together. Diabetes. 2013, 62(6): 1800-1807. doi: 10.2337/db12-1648.
50. Tomlinson DR, Gardiner NJ. Glucose neurotoxicity. Nat Rev Neurosci, 2008, 9: 36-45.
51. Cameron NE, Cotter MA. Pro-inflammatory mechanisms in diabetic neuropathy: focus on the nuclear factor kappa B pathway. Curr Drug Targets, 2008, 9: 60-67.
52. Ziegler D. Current concepts in the management of diabetic polyneuropathy. Curr Diabetes Rev, 2011 May, 7(3): 208-220.
53. Занозина О.В. Роль окислительного стресса в развитии и прогрессировании поздних осложнений сахарного диабета 2 типа. Возможности антиоксидантной терапии. Автореф. дисс… докт. мед. наук. Н. Новгород, 2010.
54. Herder C, Lankisch M, Ziegler D et al. Subclinical inflammation and diabetic polyneuropathy. Diabetes Care, 2009, 32(4): 680-682. doi: 10.2337/dc08-2011.
55. Zhang Y, Jiang Y, Shen X, Yan S. Can both normal and mildly abnormal albuminuria and glomerular filtration rate be a danger signal for diabetic peripheral neuropathy in type 2 diabetes mellitus? Neurol Sci, 2017 May 6. doi: 10.1007/s10072-017-2946-1.
56. Pop-Busui R, Lu J, Lopes N, Jones TLZ. Prevalence of diabetic peripheral neuropathy and relation to glycemic control therapies at baseline in the BARI 2D cohort. Journal of the Peripheral Nervous System, 2009, 14(1): 1-13. doi: 10.1111/j.1529-8027.2009.00200.x.
57. Inoue R, Sumitani M, Yasuda T et al. Independent risk factors for positive and negative symptoms in patients with diabetic polyneuropathy. Journal of Pain & Palliative Care Pharmacotherapy, 2016, 30(3): 178-183. doi: 10.1080/15360288.2016.1192081.
58. Abbott CA, Malik RA, Van Ross ERE, Kulkarni J, Boulton AJM. Prevalence and characteristics of painful diabetic neuropathy in a large community-based diabetic population in the U.K. Diabetes Care, 2011, 34(10): 2220-2224. doi: 10.2337/dc11-1108.
59. Sadosky A, Schaefer C, Mann R et al. Burden of illness associated with painful diabetic peripheral neuropathy among adults seeking treatment in the US: results from a retrospective chart review and cross-sectional survey. Diabetes Metab Syndr Obes, 2013, 6: 79-92.
60. Воробьева А.А., Антонова К.В. Диабетическая невропатия: состояние проблемы, перспективы. РМЖ, 2016, 24(24): 1639-1642.
61. Stark Casagrande S, Fradkin JE, Saydah SH, Rust KF, Cowie CC. The Prevalence of Meeting A1C, Blood Pressure, and LDL Goals Among People With Diabetes, 1988–2010. Diabetes Care, 2013, 36(8): 2271-2279. doi: 10.2337/dc12-2258.
62. Nedosugova LV, Lankin VZ, Balabolkin MI et al. Interrelation between compensation of carbohydrate metabolism and severity of manifestations of oxidative stress in type II diabetes mellitus. Bull Exp Biol Med, 2003, 136: 132-134.
63. Дедов И.И., Балаболкин М.И., Мамаева Г.Г., Фадеева Н.И., Клебанова Е.М., Кравченко Т.В., Креминская В.М. Антиоксидантная терапия диабета и его поздних осложнений. Пособие для врачей. М., 2001. 24 с.
64. Shakher J, Stevens MJ Update on the management of diabetic polyneuropathies. Diabetes Metab Syndr Obes, 2011, 4: 289-305.
65. Ziegler D, Luft D. Clinical trials for drugs against diabetic neuropathy: can we combine scientific needs with clinical practicalities? Int Rev Neurobiol, 2002, 50: 431-463.
66. Недосугова Л.В., Ланкин В.З., Резник С.М. и соавт. Влияние метформина на выраженность окислительного стресса у пациентов с сахарным диабетом 2-го типа. Проблемы эндокринологии, 2007, 53(1): 3-7.
67. Russo GT, Giandalia A, Romeo EL et al. Diabetic neuropathy is not associated with homocysteine, folate, vitamin B12 levels, and MTHFR C677T mutation in type 2 diabetic outpatients taking metformin. J Endocrinol Invest, 2016 Mar, 39(3): 305-314.
68. Roy RP, Ghosh K, Ghosh M et al. Study of Vitamin B12 deficiency and peripheral neuropathy in metformin-treated early Type 2 diabetes mellitus. Indian Journal of Endocrinology and Metabolism, 2016, 20(5): 631-637. doi: 10.4103/2230-8210.190542.
69. Román-Pintos LM, Villegas-Rivera G, RodríguezCarrizalez AD et al. Diabetic Polyneuropathy in Type 2 Diabetes Mellitus: Inflammation, Oxidative Stress, and Mitochondrial Function. Journal of Diabetes Research, 2016, 2016: 3425617. doi: 10.1155/2016/3425617.
70. Lenaz G, Fato R, Formiggini G, Genova ML. The role of Coenzyme Q in mitochondrial electron transport. Mitochondrion, 2007, 7: S8-S33. doi: 10.1016/j.mito.2007.03.009.
71. Hernández-Ojeda J, Cardona-Muñoz EG, RománPintos LM et al. The effect of ubiquinone in diabetic polyneuropathy: a randomized doubleblind placebo-controlled study. Journal of Diabetes and Its Complications, 2012, 26(4): 352-358. doi: 10.1016/j.jdiacomp.2012.04.004.
72. Smith AR, Shenvi SV, Widlansky M et al. Lipoic acid as a potential therapy for chronic diseases associated with oxidative stress. Current Medicinal Chemistry, 2004, 11(9): 1135-1146. doi: 10.2174/0929867043365387.
73. Ziegler D, Hanefeld M, Ruhnau KJ et al. Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant α-lipoic acid – A 3-week multicentre randomized controlled trial (ALADIN Study) Diabetologia, 1995, 38(12): 1425-1433. doi: 10.1007/BF00400603.
74. Reljanovic M, Reichel G, Rett K et al. Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (α-lipoic acid): a two year multicenter randomized double-blind placebo-controlled trial (ALADIN II) Free Radical Research, 1999, 31(3): 171-179. doi: 10.1080/10715769900300721.
75. Ziegler D, Reljanovic M, Mehnert H et al. a-Lipoic acid in the treatment of diabetic polyneuropathy in Germany: Current evidence from clinical trials. Exp. Clin. Endocrinol Diabetes, 1999, 107: 421-430.
76. Ziegler D, Hanefeld M, Ruhnau K-J et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant α-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III study). Diabetes Care, 1999, 22(8): 1296-1301. doi: 10.2337/diacare.22.8.1296.
77. Ametov AS, Barinov A, Dyck PJ et al. The sensory symptoms of diabetic polyneuropathy are improved with α-lipoic acid. The SYDNEY Trial. Diabetes Care, 2003, 26(3): 770-776. doi: 10.2337/diacare.26.3.770.
78. Ziegler D, Ametov A, Barinov A et al. Oral treatment with α-lipoic acid improves symptomatic diabetic polyneuropathy. Diabetes Care, 2006, 29(11): 2365-2370. doi: 10.2337/dc06-1216.
79. Ziegler D, Low PA, Litchy WJ et al. Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial. Diabetes Care, 2011, 34(9): 2054-2060. doi: 10.2337/dc11-0503.
80. Горбачева Ф.Е., Зиновьева О.Е., Мохова О.И., Абдулина О.В. Сравнительная оценка эффективности антиоксидантной терапии в лечении диабетической полиневропатии. Неврологический журнал, 2004, 9(1): 36-39.
81. Северина Т.И., Тарасов А.В., Трельская Н.Ю., Шилова О.Л., Дрометр Д.А. Результаты применения тиоктацида в лечении диабетической нейропатии у больных сахарным диабетом 1 типа. Сахарный диабет, 2000, 4: 33-35.
82. Sun LQ, Chen YY, Wang X, et al. The protective effect of alpha lipoic acid on Schwann cells exposed to constant or intermittent high glucose. Biochem Pharmacol, 2012, 84(7): 961-73.
83. Ruhnau KJ, Meissner HP, Finn R et al. Effects of 3-week oral treatment with the antioxidant thioctic acid (alpha-lipoic acid) in symptomatic diabetic polyneuropathy. Diabet Med, 1999, 16: 1040-1043.
84. Ibrahimpasic K. Alpha lipoic acid and glycaemic control in diabetic neuropathies at type 2 diabetes treatment. Med Arch, 2013, 67(1): 7-9.
85. Ziegler D, Nowak H, Kempler P, Vargha P, Low PA. Treatment of symptomatic diabetic polyneuropathywith the antioxidant alphalipoic acid: a meta-analysis. Diabet Med, 2004, 21(2): 114-121.
86. Ziegler D, Low PA, Boulton AJ et al. Effect of 4-year antioxidant treatment with alpha-lipoic acid in diabetic polyneuropathy: The NATHAN 1 Trial [abstract]. Diabetes, 2007, 56: A2.
87. Tankova T, Koev D, Dakovska L. Alpha-lipoic acid in the treatment of autonomic diabetic neuropathy (controlled, randomized, open-label study). Rom J Intern Med, 2004, 42(2): 457-464.
88. Ziegler D, Schatz H, Cornrad F et al. Effects of treatment with the antioxidant alpha-lipoic acid on cardiac autonomic neuropathy in NIDDM patients. A 4-month randomized controlled multicenter trial (DEKAN Study). Diabetes Care, 1997, 20(3): 369-373.
89. Ziegler D. Painful diabetic neuropathy: treatment and future aspects. Diabetes Metab Res Rev, 2008, 24(Suppl 1): 52-57.
90. Танашян М.М., Лагода О.В., Антонова К.В., Гришина Д.А. Полинейропатия и предиабетические нарушения углеводного обмена у больных с хроническими цереброваскулярными заболеваниями: диагностика и пути коррекции. Атмосфера. Нервные болезни, 2016, 2: 24-28.
91. Pop-Busui R, Boulton AJ, Feldman EL, Bril V, Freeman R, Malik RA et al. Diabetic Neuropathy: A Position Statement by the American Diabetes Association. Diabetes care, 2017, 40(1): 136-154. Epub 2016/12/22. doi: 10.2337/dc16-2042.
Рецензия
Для цитирования:
Танашян ММ, Антонова КВ, Раскуражев АА. ДИАБЕТИЧЕСКАЯ ПОЛИНЕЙРОПАТИЯ: ПАТОГЕНЕЗ, КЛИНИКА, ПОДХОДЫ К ПЕРСОНИФИЦИРОВАННОЙ КОРРЕКЦИИ. Медицинский Совет. 2017;(17):72-80. https://doi.org/10.21518/2079-701X-2017-17-72-80
For citation:
Tanashyan MM, Antonova KV, Raskurazhev AA. DIABETIC POLYNEUROPATHY: PATHOGENESIS, CLINICAL PRESETATION AND NEW APPROACHES TO PERSONALIZED TREATMENT. Meditsinskiy sovet = Medical Council. 2017;(17):72-80. (In Russ.) https://doi.org/10.21518/2079-701X-2017-17-72-80
Просмотров:
824
Послать статью по эл. почте 